46 reports

Abstract: - Global Antipsychotic Drugs Market to Reach $21.8 Billion by 2027 - Amid the COVID-19 crisis, the global market for Antipsychotic Drugs estimated at US$16.5 Billion in the year 2020, is projected to reach a revised size of US$21.8 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027....

  • Antipsychotic
  • World
  • China
  • United States

Antipsychotic Drugs Market Report Overview Antipsychotic Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Antipsychotic Drugs market types and applications. It is a focused study on Antipsychotic Drugs market space including global...

  • Antipsychotic
  • World
  • Health Provider Density

Dementia Drugs Market Report Overview Dementia Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Dementia Drugs market types and applications. It is a focused study on Dementia Drugs market space including global and regional eight-year...

  • Antipsychotic
  • World
  • Health Provider Density

Abstract: - Global Schizophrenia Therapeutics Market to Reach $11.1 Billion by 2027 - Amid the COVID-19 crisis, the global market for Schizophrenia Therapeutics estimated at US$9.6 Billion in the year 2020, is projected to reach a revised size of US$11.1 Billion by 2027, growing at a CAGR of 2% over the analysis period...

  • Antipsychotic
  • World
  • China
  • United States

Abstract: - Global Bipolar Disorder Therapeutics Market to Reach $5.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$5.4 Billion by 2027, growing at a CAGR of 1% over the analysis...

  • Bipolar Disorder
  • Antipsychotic
  • World
  • China
  • United States

Abstract: Global CNS Therapeutics Market to Reach US$144.2 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for CNS Therapeutics estimated at US$103.4 Billion in the year 2020, is projected to reach a revised size of US$144.2 Billion by 2027, growing at a CAGR of 4.9% over...

  • Pharmaceutical
  • Antipsychotic
  • Analgesic
  • World
  • China

Report Scope: This report provides a detailed description of the market for antipsychotic drugs.The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline...

  • Antipsychotic
  • World
  • APAC
  • North America
  • Europe

Antipsychotics Import

  • Mental Health
  • Antipsychotic
  • Antidepressant
  • Psychotic Disorder
  • Dementia
  • China
  • Labour Force
  • Industrial Production

The comprehensive research report on global schizophrenia treatment market by Persistence Market Research assists the reader in chalking key growth strategies on the basis of vital insights on every market segment at a global level thus providing the much necessary value addition to gain tempo in the changing dynamics of the global market...

  • Antipsychotic
  • World

China Antipsychotic

  • Mental Health
  • Antipsychotic
  • China
  • Industrial Production
  • Labour Force

Albemarle Corporation Orocobre Livent Ganfeng APAC Lithium Lithium-Ion Battery Antipsychotic

  • Lithium
  • Antipsychotic
  • APAC
  • Metal Demand
  • Lithium Demand

This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....

  • Antipsychotic
  • Respiratory Disease
  • Packaging
  • World

World Dementia Antipsychotic

  • Dementia
  • Antipsychotic
  • China
  • World
  • United States
  • Labour Force
  • Industrial Production

China Antipsychotic

  • Antipsychotic
  • China
  • Labour Force
  • Industrial Production

Antipsychotics with novel MoA

  • Antipsychotic
  • APAC
  • Drug Approval
  • Health Expenditure

Second-generation antipsychotic drugs

  • Antipsychotic
  • World
  • Drug Approval
  • Schizophrenia Prevalence

This study covers the world outlook for geriatric medicines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative...

  • Antipsychotic
  • Spacecraft
  • Satellite Launch
  • Mouth Disease
  • Respiratory Disease
  • Beef
  • Packaging
  • World
  • Gross Domestic Product
  • Disposable Income

Drug Overview ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes. Samidorphan is a novel, potent mu-opioid antagonist, while olanzapine is an atypical antipsychotic with antagonist activity at the dopamine D2 and serotonin 5-HT2A receptors. ALKS...

  • Antipsychotic
  • United States

The Global Antipsychotic Drugs Market is poised to grow at a CAGR of around 2.5% over the next decade to reach approximately $14.91 billion by 2025. This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical...

  • Antipsychotic
  • World

Drug Overview: Vraylar

8770 10000 7800

Drug Overview  Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics...

  • Antipsychotic
  • Depression

Drug Overview: Zyprexa

8770 10000 7800

Drug Overview Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval...

  • Antipsychotic
  • Bipolar Disorder

Drug Overview: Lonasen

8770 10000 7800

Drug Overview  Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist. The drug possesses a stronger blocking action to D2 receptors than to 5-HT2 receptors, and is structurally unrelated to typical antipsychotics or to newer agents such as risperidone....

  • Antipsychotic
  • Japan

Drug Overview  Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation...

  • Bipolar Disorder
  • Antipsychotic
  • Cardiovascular Drug
  • Hormone
  • United States
  • European Union

Drug Overview: Rexulti

8770 10000 7800

Drug Overview  Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous...

  • Antipsychotic
  • Neurology
  • Clinical Trial
  • Depression
  • United States

Drug Overview  Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulator of the dopaminergic and glutamatergic systems, and a serotonin reuptake inhibitor. By targeting...

  • Psychotic Disorder
  • Hormone
  • Antipsychotic

Drug Overview: Latuda

8770 10000 7800

Drug Overview  Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia...

  • Antipsychotic
  • Cardiovascular Drug
  • Psychotic Disorder
  • Hormone
  • Europe
  • European Union
  • United Kingdom
  • Italy

Drug Overview  Lamictal (GlaxoSmithKline) contains lamotrigine, a phenyltriazine antiepileptic drug that acts at voltage-sensitive sodium channels to stabilize neuronal membranes and inhibits the release of excitatory amino acid neurotransmitters. Lamictal initially launched as an adjunctive treatment for epilepsy...

  • Bipolar Disorder
  • Antipsychotic
  • Hospital
  • United States
  • European Union

Drug Overview: Saphris

8770 10000 7800

Drug Overview  Saphris (Allergan/Lundbeck/Meiji Seika) contains the atypical antipsychotic asenapine, which acts as a dopamine D2 and serotonin 5-HT2A antagonist. The drug was originally developed by Organon and Schering-Plough, and became part of Merck&Co’s portfolio after the company’s $41bn acquisition of Schering-Plough...

  • Antipsychotic
  • United States
  • European Union

Drug Overview  Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A receptor. Abilify’s partial agonist activity at the D2 receptors allows it to act as a dopamine stabilizer...

  • Antipsychotic
  • Cardiovascular Drug
  • Bipolar Disorder
  • United States
  • European Union

Drug Overview  Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors. The relatively low D2 receptor occupancy of Lu AF35700, compared to at the D1 receptor, is expected to result in a diminished burden of side effects...

  • Antipsychotic
  • Drug Development
  • Psychotic Disorder
  • Cardiovascular Drug
  • Healthcare
  • Hormone